Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock By Investing.com

SOUTH SAN FRANCISCO – Annie McGuire, Executive Vice President and General Counsel at Veracyte, Inc. (), recently sold shares of the company’s common stock totaling $140,212, according to a filing with the Securities and Exchange Commission. The stock currently trades at $42.53, up 31% over the past year.

On September 4, 2026, Ms. McGuire executed two separate sales. She sold 2,154 shares at prices ranging from $42.49 to $43.38 per share. Additionally, she sold 1,100 shares at prices ranging from $43.50 to $44.16 per share. These transactions were carried out under a Rule 10b5-1 trading plan, which Ms. McGuire adopted on August 29, 2025. The company trades at a P/E ratio of 30.67 and appears slightly overvalued according to InvestingPro Fair Value analysis.

The filing also reported a disposition of 3,215 shares of common stock on September 2, 2026. These shares, valued at $44.88 each for a total of $144,289, were withheld to cover tax withholding obligations related to the vesting of restricted stock units and do not represent a market sale.

Following these reported transactions, Ms. McGuire beneficially owns 131,160 shares of Veracyte common stock. This total includes 389 shares acquired through the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2026.

In other recent news, Veracyte has reported its second-quarter 2026 results, surpassing Wall Street expectations. The company achieved adjusted earnings of $0.54 per share on revenue of $150.3 million, exceeding forecasts of $0.43 per share and $144.6 million in revenue. Following these strong results, Veracyte has raised its full-year revenue outlook. Analysts have responded to these developments with mixed reactions. Freedom Capital increased its price target for Veracyte to $66, citing the company’s strong earnings and revenue performance. Similarly, Needham raised its price target to $69, highlighting the significant beat in revenue and earnings per share. However, Canaccord lowered its price target to $50, driven by a more cautious revenue outlook in the long term. Despite these varied analyst opinions, Veracyte’s recent financial performance has been notably strong.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.